CFL1 and hepatocellular carcinoma: All these results suggest that CFL1 could be a biomarker to predict the sensitivity of HCC cells to TKIs and silencing CFL1 expression could be a universal method to enhance the therapeutic outcomes of TKIs for advanced HCC.